Does Indiana Medicaid Cover Ozempic or Wegovy for Weight Loss in 2026
A Marion County resident's guide to HIP 2.0 coverage, prior authorization, pharmacy availability, and what you'll actually pay out of pocket
A Marion County resident’s guide to HIP 2.0 coverage, prior authorization, pharmacy availability, and what you’ll actually pay out of pocket
The short answer is no. Indiana Medicaid does not cover Ozempic, Wegovy, or any other GLP-1 drug for weight loss alone in 2026. If you have a documented Type 2 diabetes diagnosis, you may qualify — but the path to coverage runs through a prior authorization process that varies by insurer, requires specific clinical documentation, and takes longer than most patients expect. If you don’t have diabetes, or if you’re uninsured, you’re in a cash market where brand-name drugs run close to $1,000 a month or more.
That gap between what national telehealth ads imply and what Medicaid actually covers is what this piece is for.
What Changed in 2026 and What Stayed the Same
The Centers for Medicare and Medicaid Services proposed allowing states to cover anti-obesity medications under Medicaid starting in 2026. Indiana did not opt in. Per the last available FSSA guidance, HIP 2.0’s longstanding restriction remains: GLP-1 receptor agonists are covered only when prescribed for Type 2 diabetes — not obesity or weight management as a standalone diagnosis.
HIP 2.0 is not a single uniform plan, which trips people up constantly. Indiana contracts with three managed care entities — Anthem, MHS (Managed Health Services), and MDwise (now operating under Centene). Each publishes its own preferred drug list. The formulary tier, cost-sharing, and prior authorization criteria for Ozempic differ depending on which MCE issued your HIP 2.0 card. If you’ve seen a telehealth ad suggesting Medicaid covers these drugs for weight loss, or promising easy access through a quick online questionnaire, that ad is not describing Indiana’s program. Not even close.
The Diabetes Diagnosis Divide
The policy creates a practical split between drugs that are nominally the same molecule and drugs that are legally distinct products. Ozempic (semaglutide, injection) and Mounjaro (tirzepatide, injection) are FDA-approved for Type 2 diabetes management. HIP 2.0 patients with a documented T2D diagnosis may be eligible for these under the managed care formularies, subject to prior authorization. Wegovy (higher-dose semaglutide) and Zepbound (tirzepatide, higher dose) are FDA-approved specifically for chronic weight management. Same or closely related active ingredients — but their National Drug Codes fall under obesity pharmacotherapy, which disqualifies them under HIP 2.0 in 2026.
Rybelsus, the oral form of semaglutide, carries a T2D indication and appears on some MCE formularies. Tier placement varies. MHS and Anthem have historically approved it with prior authorization; MDwise/Centene’s preferred drug list should be verified directly, since these get updated mid-year without much fanfare.
One thing worth flagging for prescribers at safety-net clinics — and a recurring theme in our Indianapolis health and wellness coverage of medication access and insurance navigation: the diagnosis code on the submission — not just the drug name — determines whether the claim clears. A primary care provider at Eskenazi or Neighborhood Health documenting a T2D diagnosis needs to make sure that code is explicit and primary in the prior authorization submission, not buried under BMI notes or metabolic syndrome documentation. Incomplete diagnosis coding is the most common reason these claims are delayed or initially denied. Not the most dramatic reason, but far and away the most fixable one.
The Prior Authorization Process, Step by Step
Prior authorization for a GLP-1 drug under HIP 2.0 does not go to FSSA. It goes to the patient’s MCE — Anthem, MHS, or MDwise/Centene — each of which administers its own PA criteria. All three are bound by Indiana’s required three-business-day turnaround for standard approvals. In practice, that clock doesn’t start until the submission is complete.
The documentation package needs a confirmed Type 2 diabetes diagnosis with the ICD-10 code appearing on the clinical record and on the PA request form. Not “obesity with metabolic risk.” Not “prediabetes.” Type 2 diabetes. Each MCE sets its own HbA1c threshold — often 7.0 or 8.0 — but this changes with each plan year’s PA criteria document. Pull the current version from your MCE’s provider portal before submitting. What the criteria said last year may not apply now.
All three MCEs require evidence that the patient has tried metformin, the standard first-line medication for T2D. “Failure” can mean inadequate glycemic control on maximum tolerated dose, or documented intolerance. Vague notes saying “patient couldn’t tolerate metformin” get kicked back; providers should include specific dosing history and the reason for discontinuation. Providers at Eskenazi have told me this is where more submissions fall apart than anywhere else.
Most PA forms also require the patient’s current BMI and a prescriber attestation that the GLP-1 is being prescribed for diabetes management, not weight loss. That clinical framing matters more than most people realize. The prescribing provider must have an active NPI enrolled with the MCE and an established patient relationship. Telehealth-only prescribers who are not enrolled with Indiana Medicaid cannot initiate a valid PA request — worth knowing if you’ve already started down that road.
Submit a complete package upfront and the three-day turnaround is achievable. Incomplete submissions trigger back-and-forth that can drag across months. Three business days versus three months is not a small difference when someone is waiting on medication.
Indiana does not publish denial rates for GLP-1 prior authorization requests by MCE. Neither FSSA nor the individual managed care entities release that data in any form accessible to patients or journalists. There’s no way to know whether one MCE is approving 80% of requests and another is approving 30%. That’s a real transparency problem, and I don’t have a satisfying answer for it — only the acknowledgment that it makes an already opaque process harder to navigate.
If a claim is denied: Indiana Legal Services has handled GLP-1 coverage denial appeals for Medicaid patients and is worth contacting. You have the right to appeal through the MCE’s internal appeal process first, then through a state fair hearing if that fails. Providers who document clinical necessity thoroughly win a real share of these appeals. A denial is not the end of the road, but the appeal deadline — usually 30 to 60 days from the denial notice — is firm.
Where to Start in Marion County
Eskenazi Health is the county hospital and safety-net system for Marion County, with internal medicine and endocrinology across its main campus at 720 Eskenazi Ave. and several community health centers. Its staff has direct experience with HIP 2.0 prior authorization workflows for these specific drugs — and that matters. A practice that has submitted dozens of GLP-1 PA requests knows how each MCE actually processes documentation. That institutional knowledge is genuinely useful, not just a talking point. If you’re already an Eskenazi patient, your primary care provider or endocrinologist is the right starting point.
Neighborhood Health Indianapolis is a federally qualified health center with clinics in Fountain Square, the near-Eastside, and south Indianapolis. FQHCs have a specific structural advantage here: 340B drug pricing. Under the federal 340B program, FQHCs can purchase outpatient medications at sharply discounted prices and pass those savings to patients. For HIP 2.0 patients whose coverage is partial, delayed, or in appeal, the cost-share on a GLP-1 through a 340B pharmacy can be meaningfully lower than a standard Medicaid copay at a chain pharmacy — and nowhere near cash price. Neighborhood Health’s scheduling number is 317-635-3158.
IU Health’s Medical Weight Management program offers both surgical and non-surgical pathways and accepts multiple insurance types. Patients weighing their options across the major Indianapolis systems may find it useful to review how Eskenazi, IU Health, Community, Franciscan, and other networks compare before deciding where to seek care. Call IU Health directly for current self-pay pricing.
Which Marion County Pharmacies Stock These Drugs
National supply shortages for semaglutide and tirzepatide — genuinely disruptive through 2023 and 2024 — have eased going into 2026. Novo Nordisk has reported sustained supply for Ozempic and Wegovy pen formulations, and FDA shortage data no longer lists the primary semaglutide NDCs as in shortage. Tirzepatide availability has also stabilized. Lower starting-dose pen sizes can still be intermittently out of stock at individual locations.
Eskenazi Health’s outpatient pharmacy on the main campus is the most reliable source for HIP 2.0 patients already in that system. It stocks these drugs for formulary-covered patients and can process PA approvals directly with the Eskenazi clinical team. When your prescriber and your pharmacy are in the same system, submission errors and communication delays drop significantly — a small thing that ends up saving a lot of phone calls.
Kroger pharmacies at Broad Ripple (1010 Broad Ripple Ave.) and Castleton (5415 E. 82nd St.) stock semaglutide and tirzepatide products; ask specifically about your pen size. CVS routes some specialty products through CVS Specialty pharmacy, which runs on a separate system with its own processing timeline. If your prescription gets sent to Specialty, the logistics differ from a standard retail pickup and the fill can take several days — worth knowing before you’re standing at the counter expecting same-day. Walgreens locations in Broad Ripple and near Washington Square Mall have carried semaglutide products consistently through 2025–2026, though specific pen sizes have occasionally required a day or two for reorder.
Call the pharmacy’s direct line — not the national 800 number — before your prescriber sends the prescription. This call takes five minutes and can save a week of logistics. No exceptions.
What You’ll Pay Out of Pocket If You Don’t Qualify
Ozempic (semaglutide, diabetes formulation) runs around $950 per month at Marion County chain pharmacies. GoodRx pricing checked at zip codes 46201 (near-Eastside), 46208 (Mapleton-Fall Creek), and 46227 (Perry Township) shows prices in this range across Kroger, CVS, and Walgreens, with the 0.5mg starting-dose pen typically at the lower end and the 1mg and 2mg pens higher.
Wegovy (semaglutide, obesity formulation) runs close to $1,350 per month. This is the drug most patients see advertised — and the most expensive. Worth knowing before you ask your doctor for it by name. Mounjaro and Zepbound (both tirzepatide formulations) run roughly $1,050 to $1,100 per month at retail.
Novo Nordisk and Eli Lilly both offer savings programs that can reduce costs substantially for commercially insured patients. These programs are legally prohibited for Medicaid enrollees. Using one while enrolled in HIP 2.0 — even if your specific claim was denied — is a federal compliance violation, and pharmacies will flag this at point of sale. This catches people off guard, so it’s worth being direct about it.
Several direct primary care practices in Indianapolis, including options in Broad Ripple and the near-Northside, offer GLP-1 prescribing as part of a DPC membership, typically around $100 to $130 per month for the membership itself. Drug cost is separate, sometimes at wholesale passthrough pricing. These practices aren’t set up to navigate Medicaid PA, but for cash-pay patients they offer faster access and more regular monitoring than a traditional clinic. If you’re considering this route, ask for a total monthly estimate including the drug — the membership fee and the pharmacy cost are separate line items.
Medical weight-loss clinics and med spas in Broad Ripple and Nora typically charge $150 to $300 per month in program fees before the drug cost. Some bundle monitoring visits and labs; others charge separately. If you’re paying cash, ask specifically what the monthly total looks like all-in, because the number that gets advertised and the number you actually pay are often different.
Compounded Semaglutide in Indianapolis
The FDA declared the semaglutide shortage resolved in 2025. After that declaration, compounding pharmacies — including 503A retail compounders — were no longer permitted to compound copies of semaglutide for individual patient prescriptions. The FDA issued enforcement guidance and began taking action against pharmacies and telehealth platforms that kept selling compounded semaglutide anyway.
The 503B outsourcing facility pathway is more complicated. Larger-scale compounders can produce drugs for office use without individual prescriptions, and the regulatory status at specific 503B facilities requires direct verification as of 2026. If a compliant pathway remains open for a particular formulation or salt form, prices have historically run around $300 per month — which is why people keep looking for this option.
Here’s the practical advice: if a telehealth platform is advertising compounded semaglutide for $200 a month with easy online prescribing, ask directly whether the filling pharmacy is 503B licensed and whether the FDA has issued warning letters affecting that facility. Some platforms continued marketing compounded semaglutide after the regulatory window closed. That creates a compliance risk for patients, not just the pharmacy. The FDA’s 503B outsourcing facility database is publicly searchable — takes about two minutes. Do it before you order anything.
A Practical Decision Tree for Marion County Residents
If you’re on HIP 2.0 with a documented Type 2 diabetes diagnosis: Contact Eskenazi Health or Neighborhood Health (317-635-3158) and ask for an appointment with internal medicine or endocrinology to discuss GLP-1 therapy. Bring your medication history, recent HbA1c results, and your insurance card. Ask the provider whether they’ve submitted GLP-1 prior authorizations to your specific MCE before — it’s a reasonable question. If your claim is denied, contact Indiana Legal Services before the appeal deadline. That deadline is real and it won’t be extended.
If you’re on HIP 2.0 without a Type 2 diabetes diagnosis: GLP-1 coverage for weight management alone isn’t available under 2026 Indiana Medicaid policy. If you have prediabetes or significant metabolic risk, ask your provider whether a diabetes diagnosis is clinically supported by your labs — that’s a medical question, not a workaround. If you’re cash-pay, the out-of-pocket pricing section above applies. You can also call FSSA member services at 800-403-0864 to ask about any additional benefits under your specific plan, though the formulary restriction is consistent across MCEs.
If you’re uninsured or underinsured near the Medicaid threshold: Start with Neighborhood Health Indianapolis, which treats patients on a sliding-fee scale regardless of insurance status. The FQHC model means your visit cost is income-based, and 340B pricing can reduce medication costs if you’re enrolled in Medicaid or Medicare. If you’re not enrolled in Medicaid and think you may qualify, call FSSA at 800-403-0864. HIP 2.0 income eligibility in 2026 is 138% of the federal poverty level for adults 19 to 64.
If you’re paying entirely out of pocket: Compare the DPC membership model against standard chain pharmacy cash pricing. For a patient who needs regular monitoring visits, the DPC model can come out ahead of paying per-visit clinic rates on top of pharmacy costs. Call a DPC practice and ask for a total monthly estimate including the drug at their passthrough price. Then run your specific dose through GoodRx at your home zip code. Price variation is real — sometimes $100 or more across just a few miles.
FSSA member services: 800-403-0864. Indiana Legal Services Indianapolis office: indianalegalservices.org. Neighborhood Health Indianapolis: 317-635-3158.
